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ABSTRACT 
Objective: The objective of the study was to evaluate the individual main effects and combined (or interaction) effects of cyclodextrin (β 
cyclodextrin), surfactant (Poloxamer 407) and polyvinylpyrrolidone K30 (PVP K30) on the solubility and dissolution rate of pioglitazone in a series 
of 23 factorial experiments. The inclusion complexes were evaluated for pharmacokinetics and in vivo performance in comparison to pioglitazone 
pure drug. 
Methods: Among the various approaches complexation with cyclodextrins has gained good acceptance in recent years in the industry for enhancing 
the solubility and dissolution rate of poorly soluble drugs. As per the phase solubility studies, a 23 factorial study was used to prepare the solid 
inclusion complexes and evaluated for the interactions and in vitro drug release. The best combinations were selected for in vivo performance in 
healthy albino rabbits. From the time versus plasma concentration data, various pharmacokinetic parameters such as peak concentration (Cmax), 
time at which peak occurred (Tmax), area under the curve (AUC), elimination rate constant (Kel), biological half-life (t1/2), percent absorbed to various 
times and absorption rate constant (Ka) were calculated in each case. 
Results: The solubility of pioglitazone in eight selected fluids containing β cyclodextrin (βCD), Poloxamer 407 and PVP K30 as per 23 factorial 
studies was determined. Combination of βCD with Poloxamer 407 and PVP K30 resulted in a much higher enhancement (13.85-7.06 folds) in the 
solubility of pioglitazone than the βCD alone. Solid inclusion complexes of pioglitazone-βCD were prepared with and without Poloxamer 407 and 
PVP K30 by kneading method as per 23- factorial design. Analysis of variance (ANOVA) indicated that the individual main effects of βCD, Poloxamer 
407 and PVP K30 and their combined effects in enhancing the solubility and dissolution rate (K1) were highly significant (P<0.01). The t1/2 value of 
pioglitazone estimated (6.92-7.46 h) in the present study was in good agreement with the literature reported value of 6-10 h. Pioglitazone was 
absorbed slowly when given orally with an absorption rate constant (Ka) of 0.629 h-1 and a peak plasma concentration (Cmax) of 11.40±0.7 µg/ml 
was observed at 4.0 h after administration. All the pharmacokinetic parameters namely Cmax, Tmax, Ka and (AUC)0∞ indicated rapid and higher 
absorption and bioavailability of pioglitazone when administered as βCD complexes. A 3.43 and 4.67 fold increase in the absorption rate (Ka) and a 
1.49 and 1.67 fold increase in (AUC)0∞ was observed respectively with pioglitazone-βCD (1:2) and pioglitazone-βCD (1:2)-Poloxamer 407 (2%) 
complexes when compared to pioglitazone pure drug.  
Conclusion: Combination of βCD with Poloxamer 407 gave higher rates of absorption and bioavailability of pioglitazone than is possible with βCD 
alone. Hence the combination of βCD with Poloxamer 407 is recommended to enhance the absorption and bioavailability of pioglitazone, a BCS class 
II drug. 
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Pioglitazone is used to treat type 2 diabetes; condition in which the 
body does not use insulin normally and therefore cannot control the 
amount of sugar in the blood. Pioglitazone belongs to 
thiazolidinedione class. Pioglitazone, a water-insoluble antidiabetic 
drug belongs to class IΙ under biopharmaceutics classification system 
(BCS) and exhibit low and variable oral bioavailability due to its 
poor aqueous solubility. As such its oral absorption is dissolution 
rate limited and it requires enhancement in solubility and 
dissolution rate for increasing its oral bioavailability. Among the 
various approaches complexation with cyclodextrins were used for 
enhancing the solubility and dissolution rate of poorly soluble drugs. 
The inclusion complex hides most of the hydrophobic functionality 
in the interior cavity of the cyclodextrin (CD) while the hydrophilic 
hydroxyl groups on the external surface remain exposed to the 
environment and result in the formation of water-soluble CD drug 
complex [1].  
In addition to improving solubility, CDs also impede crystallization 
of active ingredients by complexing individual drug molecules so 
that they can no longer self-assemble into a crystal lattice [2]. 
Cyclodextrins have been receiving an increasing application in 
pharmaceutical formulation due to their approval by several 
regulatory agencies [3, 4]. Poloxamer 407 is a polyethene oxide-
polypropylene oxide-polyethene oxide triblock copolymer of non-
ionic nature and is used as a solubilizing agent [5-8]. 
Polyvinylpyrrolidone (PVP K30) are also reported [9-12] earlier to 
enhance the solubility of poorly soluble drugs.  
Though cyclodextrin complexation and use of surfactants for 
enhancing the solubility and dissolution rate of poorly soluble drugs 
have been investigated individually, only a few reports are available 
on their combined use in enhancing the solubility and dissolution 
rate. We reported [13] earlier that combination of cyclodextrins 
(βCD and HPβCD) with Poloxamer 407 has markedly enhanced the 
solubility and dissolution rate of pioglitazone, a BCS class II drug 
than is possible with them individually. The objective of the present 
study was to evaluate the pharmacokinetics and in vivo performance 
of the Pioglitazone-βCD-Poloxamer 407 inclusion complexes in 
comparison to pioglitazone pure drug in healthy albino rabbits. 
MATERIALS AND METHODS 
Materials 
Pioglitazone was a gift sample from M/s. Hetero Drugs Ltd., 
Hyderabad. β cyclodextrin was gift sample from M/s. Cerestar Inc., 
USA. Methanol (Qualigens), polyvinylpyrrolidone (PVP K30) and 
Poloxamer 407 were procured from commercial sources. Normal 
albino rabbits were procured from National Institute of Nutrition, 
Hyderabad, India. Pellet diet was procured from Rayan’s 
Biotechnologies Pvt. Ltd., Hyderabad, India. All other materials used 
were of the Pharmacopoeial grade. 
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Estimation of pioglitazone 
A UV spectrophotometric method based on the measurement of 
absorbance at 269 nm in 0.1 N hydrochloric acid of pH 1.2 was used 
for the estimation of pioglitazone. The method was validated for 
linearity, accuracy, precision and interference. The method obeyed 
Beer’s law in the concentration range of 1-10 µg/ml. When a 
standard drug solution was repeatedly assayed (n= 6), the relative 
error and coefficient of variance were found to be 0.68% and 1.02% 
respectively. No interference by the excipients used in the study was 
observed. 
Phase solubility studies 
Phase solubility studies were performed according to the method 
reported by Higuchi and Connors [14]. Excess drug (25 mg) in each 
case was added to 15 ml of double distilled water (pH 6.8) 
containing various concentrations of βCD (1-15 mmol) or Poloxamer 
407 or PVP K30 (0-10% w/v) taken in a series of 50 ml stoppered 
conical flasks and the mixtures were shaken for 72 h at room 
temperature (28 °C) on a rotary flask shaker. After 72 h of shaking to 
achieve equilibrium, 2 ml aliquots were withdrawn at 1 h interval 
and filtered immediately using 0.45 µ nylon disc filters. The filtered 
samples were diluted suitably and assayed at 269 nm for 
pioglitazone against blanks prepared in the same concentration of 
CDs/Poloxamer 407/PVP K30 in water so as to cancel any 
absorbance that may be exhibited by the cyclodextrin/Poloxamer 
407/PVP K30 molecules. Shaking was continued until three 
consecutive estimations were the same. The solubility experiments 
were conducted in triplicate. 
Solubility determination 
From the phase solubility data concentration of the βCD, Poloxamer 
407 and PVP K30 were confirmed. Each fluid was prepared by 
known concentration of βCD/Poloxamer 407/PVP K30 as per 23 
factorial design. Excess drug (50 mg) was added to 15 ml of each 
fluid, taken in a 25 ml stoppered conical flask and the mixtures were 
shaken for 24 h at room temperature (28±1 °C) on rotary flask 
shaker. After 24 h of shaking, 2 ml aliquots were withdrawn at 2 h 
interval and filtered immediately using a 0.45 µ disk filter. The 
filtered samples were diluted suitably and assayed for pioglitazone 
by measuring absorbance at 269 nm. Shaking was continued until 
two consecutive estimations are the same. The solubility 
experiments were replicated for four times each (n= 4). 
Preparation of pioglitazone-CD complexes 
Solid inclusion complexes of pioglitazone-βCD were prepared in 1:2 
ratio with and without Poloxamer 407 (2%) and PVP K30 (2%) by 
kneading method. Pioglitazone, βCD, Poloxamer 407 and PVP K30 
were triturated in a mortar with a small volume of a solvent 
consisting of a blend of water: methanol (1:1 v/v). The thick slurry 
formed was kneaded for 45 min and then dried at 55 °C until dry. 
The dried mass was powdered and sieved to mesh No. 120. 
Characterization 
Fourier-transform infrared (FTIR) analysis 
FTIR studies were performed using a Perkin Elmer FTIR 
spectrophotometer to investigate the interaction of pioglitazone 
with the polymers. The samples were pelletized with KBr and the 
pellet was analyzed at a scanning range of 450-4000 cm-1. 
Characteristic peaks of the respective samples were recorded.  
Differential scanning calorimetry (DSC) analysis 
DSC analysis was carried out using Perkin Elmer, the system in the 
temperature range 30-250 °C at a heating rate of 10 °C/min in a 
dynamic nitrogen atmosphere. Approximately 5 mg of powder 
sample was accurately weighed and crimped in the aluminium lid, 
and an empty sealed aluminium pan was used as the reference. 
Dissolution rate study 
The dissolution rate of pioglitazone as such and from βCD complex 
prepared was studied in 900 ml 0.1 N hydrochloric acid of pH 1.2 
using Disso 2000 (Labindia) 8-station dissolution test apparatus 
with a paddle stirrer at 50 rpm. A temperature 37±1 °C was 
maintained throughout the study. Pioglitazone or pioglitazone 
factorial combinations equivalent to 30 mg of pioglitazone was used 
in each test. Samples of dissolution media (5 ml) were withdrawn 
through a filter (0.45 µ) at different intervals of time, suitably diluted 
and assayed for pioglitazone at 269 nm. The sample of dissolution 
fluid withdrawn at each time was replaced with fresh fluid. The 
dissolution experiments were replicated three times each (n=3). 
Preparation of pioglitazone-βCD-poloxamer 407/PVP K30 tablets 
Compressed tablets each containing 30 mg of pioglitazone were 
prepared as per 23-factorial study by (i) wet granulation and (ii) 
direct compression methods employing pioglitazone-βCD-
Poloxamer 407/PVP K30 inclusion complexes. The composition, 
processing information and the results were already reported [15].  
Pharmacokinetic study 
Pharmacokinetic evaluation of (i) pioglitazone-βCD (1:2) and (ii) 
pioglitazone-βCD (1:2)-Poloxamer 407 (2%) inclusion complexes in 
comparison to pioglitazone pure drug was done in healthy albino rabbits 
weighing 1.5-2.5 kg (n= 6) of either sex in a crossover randomized block 
design [16] at a dose equivalent to 10 mg/kg of pioglitazone. The animals 
were procured from National Institute of Nutrition, Hyderabad, India 
and kept in individual cages 30 d prior to the study. The animals were 
maintained under standard laboratory conditions and were fed with a 
commercial pellet diet and water ad libitum. A constant day-night cycle 
was maintained and the temperature of the animal room was kept 
constant throughout the study period. In vivo study protocols were 
approved by the Institutional Animal Ethics Committee (Regd. No 
516/01/a/CPCSEA). A washout period of one month was given between 
testing of two products. 
Overnight fasted healthy animals were used for the dosing. After 
collecting the zero hour blood sample (blank), the product in the 
study was administered orally in a capsule shell with 10 ml of water. 
No food or liquid other than water was permitted until 4 h following 
the administration of the product. Blood samples (2 ml) were 
collected from marginal ear vein at 0.5, 1, 2, 3, 4, 6, 8 and 12 h after 
administration. The blood samples were collected in heparinized 
tubes and were centrifuged at 10000 rpm for 10 min and the plasma 
separated was collected into dry tubes. All the samples were stored 
under refrigerated conditions prior to assay on the same day. Plasma 
concentrations of pioglitazone were determined by a known [17] 
high-performance liquid chromatography (HPLC) method after 
revalidation as follows. 
Instrumentation and chromatographic conditions 
The HPLC system (Make: M/s Shimadzu Corporation, Japan.) consisted 
of UV-Visible detector (Shimadzu, Model: SPD–10AVP), C-18 column 
(Phenomenex, DESC: Gemini 5µ C18 110 A°, Size: 250 X 4.6 mm, S/No: 
288063–23), 2 pumps (Model: LC–10 ATVP) and a microsyringe of 
capacity 25 µl (Model: Microliter® # 702, Mfd. by: M/s Hamilton). 
The mobile phase consists of a mixture of acetonitrile-water (60: 40 
v/v) adjusted to pH 6.0 with 0.1% v/v glacial acetic acid. The mobile 
phase was filtered through a 0.45 µm membrane filter before use 
and was run at a flow rate of 1 ml/min. Amikacin (4 µg/ml) was used 
as internal standard. The column effluent was monitored at 269 nm. 
The retention time of pioglitazone is 5.310 min. The retention time 
of internal standard is 3.342 min. 
Estimation of pioglitazone in plasma 
HPLC chromatogram of pioglitazone at a concentration of 1 µg/0.5 
ml of plasma is shown in fig. 6. For the estimation of pioglitazone in 
plasma samples, a calibration curve was constructed initially by 
analyzing plasma samples containing different amounts of 
pioglitazone as follows:  
To a series of tubes containing 0.5 ml of drug-free plasma in each, 0.1 ml 
of an internal standard solution containing 4 µg of amikacin and 0.1 ml 
drug solution containing 1, 2, 3, 4, 5 and 6 µg of pioglitazone were added 
and mixed. To each tube, 1 ml of acetonitrile was added, mixed 
thoroughly and centrifuged at 5000 rpm for 20 min. The organic layer 
(0.5 ml) was taken into a dry tube and the acetonitrile was evaporated. 
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To the dried residue, 0.5 ml of mobile phase was added and mixed for 
reconstitution. Subsequently, 20 µl were injected into the column for 
HPLC analysis. The interday and intraday precision of the method was 
evaluated by analyzing plasma sample containing 1.0 µg/0.5 ml plasma 
of pioglitazone repeatedly (n=6).  
Data analysis 
From the time versus plasma concentration data, various 
pharmacokinetic parameters such as peak concentration (Cmax), time 
at which peak occurred (Tmax), Area under the curve (AUC), 
elimination rate constant (Kel), biological half-life (t1/2), percent 
absorbed to various times and absorption rate constant (Ka), were 
calculated in each case as per known standard methods [18, 19].  
RESULTS AND DISCUSSION 
Phase solubility studies 
The phase solubility studies of pioglitazone in presence of βCDs, 
Poloxamer 407 and PVP K30 were studied. In each case, the aqueous 
solubility of the drug was increased linearly as a function of the 
concentration of βCD as well as Poloxamer 407 and PVP K30. The phase 
solubility diagrams of the drug-βCD complex (fig. 1a) can be classified as 
type AL according to Higuchi and Connors [14]. Because the straight line 
had a slope<1, the increase in solubility was due to the formation of a 1:1 
M complex in solution with βCD. The apparent stability constant (Kc) in 
each case was calculated from the slope of the corresponding linear plot 
of the phase solubility diagram according to the equation, Kc = Slope/So 
(1-Slope), where so is the solubility of the drug in the absence of βCD. 
The estimated apparent stability Constant (Kc) value of Pio-βCD complex 
is 1658.54 M-1. The values of Kc indicated that the complexes formed 
between drug and βCD were quite stable. 
Poloxamer 407 and PVP K30 also increased the solubility of pioglitazone. 
When the concentration of Poloxamer 407 and PVP K30 has increased 
the solubility was also increased linearly. Thus the phase solubility 
studies indicated that the solubility of the pioglitazone could be 
increased by the use of βCD, Poloxamer 407 and PVP K30.  
Solubility studies 
The individual main effects and combined (interaction) effect of βCD 
(factor A), Poloxamer 407 (factor B) and PVP K30 (factor C) on the 
aqueous solubility of pioglitazone were evaluated in a series of 23-
factorial experiments. For this purpose, two levels of βCDs (0, 5 
mmol), two levels of Poloxamer 407 (0, 2%) and two levels of PVP 
K30 (0, 2%) were selected in each case and the corresponding eight 
treatments involved in the 23-factorial study were purified water 
(1); water containing 5 mmol βCD (a); water containing 2% 
Poloxamer 407 (b); water containing 5 mmol βCD and 2% 
Poloxamer 407 (ab); water containing 2% PVP K30 (c); water 
containing 5 mmol βCD and 2% PVP K30 (ac); water containing 2% 
Poloxamer 407 and 2% PVP (bc) and water containing 5 mmol βCD 
and 2% of each of Poloxamer 407 and PVP K30 (abc). 
The solubility of pioglitazone in the above-mentioned fluids was 
determined (n= 4) and the results are given in table 1. The solubility 
data were subjected to analysis of variance (ANOVA) to find out the 
significance of main and combined effects of βCD, Poloxamer 407 
and PVP K30 on the solubility of pioglitazone. The results of ANOVA 
indicated that the individual and combined effects of βCD, 
Poloxamer 407 and PVP K30 in enhancing the solubility of 
pioglitazone were highly significant (P<0.01). The solubility of 
pioglitazone was marginally enhanced by βCD (3.42 fold). Whereas 
Poloxamer 407 and PVP K30 gave a moderate enhancement (4.32 
and 9.54 fold) in the solubility of pioglitazone. The order of 
increasing solubility observed with βCD and surfactants was PVP 
K30>Poloxamer 407>βCD>. Combination of βCD with Poloxamer 
407 and PVP K30 resulted in a much higher enhancement (13.85 and 
7.06 fold) in the solubility of pioglitazone than the βCD alone. 
Characterization 
Fourier-transform infrared (FTIR) analysis 
The compatibility of drug and excipients in the drug-βCD-Poloxamer 
407-PVP K30 complexes prepared was evaluated by FTIR spectral 
studies. An FTIR spectrum of pioglitazone is shown in the fig. 1a. The 
characteristic IR absorption peaks of pioglitazone at 3364 cm-1 (N-H 
stretching vibration, presence of amide), 3084 cm-1 (C-H stretching 
vibration, presence of aromatic), 2928 cm-1 (C-H stretching, 
presence of aliphatic asymmetric), 1743 cm-1 (C= O stretching, 
presence of amide), 1616 cm-1 (C= C stretching), 1460 cm-1 (C-N 
stretching), 1242 cm-1 (C-S stretching), 1038 and 1084 cm-1 (C-O-C 
stretching, presence of di substituted aromatic ring) were observed 
in the FTIR spectra of pioglitazone. The FTIR spectra of drug-βCD-
Poloxamer 407-PVP K30 complexes (fig. 1b) also exhibited all the 
above mentioned characteristic IR absorption peaks of pioglitazone. 
The FTIR spectra thus indicated no interaction between pioglitazone 
and the excipients in the complexes prepared. 
Differential scanning calorimetry (DSC) analysis 
The compatibility of drug and excipients in the drug-βCD-Poloxamer 
407-PVP K30 complexes prepared was also evaluated by DSC 
studies. The DSC thermogram of pioglitazone (fig. 2a) exhibited a 
broad endothermic peak with two sharp divided peaks at 177.5 °C 
and 187.9 °C corresponding to its melting point of 188 °C. The DSC 
thermogram of pioglitazone-βCD-Poloxamer 407-PVP K30 (fig. 2b) 
showed a sharp endothermic peak at 178.3 °C corresponding to βCD. 
The DSC thermograms thus indicate no interaction between 
pioglitazone and βCD, Poloxamer 407 and PVP K30 in the complexes.  
Dissolution rate study of solid inclusion complexes 
To evaluate the individual and combined effects of βCD, Poloxamer 
407 and PVP K30 on the dissolution rate of pioglitazone, solid 
inclusion complexes of pioglitazone-βCD were prepared with and 
without Poloxamer 407 and PVP K30 as per 23-factorial design. For 
this purpose two levels of βCD (0 and 1:2 ratio of drug: βCD) and 
two levels of each of Poloxamer 407 and PVP K30 (0 and 2%) were 
selected and the corresponding eight treatments involved in the 23-
factorial study were pioglitazone pure drug (1); pioglitazone βCD 
(1:2) inclusion binary complex (a); pioglitazone-Poloxamer 407 
(2%) binary mixture (b); pioglitazone-βCD (1:2)-Poloxamer 407 
(2%) ternary complex (ab); pioglitazone-PVP K30 (2%) binary 
mixture (c); pioglitazone-βCD (1:2)-PVP K30 (2%) ternary complex 
(ac); pioglitazone-Poloxamer 407 (2%)-PVP K30 (2%) ternary 
complex (bc) and pioglitazone-βCD (1:2)-Poloxamer 407 (2%)-PVP 
K30 (2%) complex (abc). 
The βCD complexes were prepared by kneading method. All the solid 
inclusion complexes of pioglitazone-βCD-Poloxamer 407-PVP K30 
prepared were found to be fine and free-flowing powders. Low 
coefficient of variation (c. v.) values (<1%) in the percent drug 
content indicated uniformity of drug content in each batch of solid 
inclusion complexes prepared. The dissolution rate of pioglitazone 
alone and from βCD complexes was studied in 0.1 N hydrochloric 
acid of pH 1.2. The dissolution of pioglitazone followed first-order 
kinetics with ‘r’ (correlation coefficient) above 0.92. Dissolution 
efficiency (DE30) values were calculated as suggested by Khan [20]. 
The dissolution parameters are given in table 2 and the graphs were 
given in fig. 3. The dissolution of pioglitazone was rapid and higher 
in the case of pioglitazone-βCD binary and ternary complex systems 
prepared when compared to pioglitazone pure drug as such. 
The dissolution rate (K1) values were subjected to ANOVA to find out 
the significance of the main and combined effects of βCD, Poloxamer 
407 and PVP K30 on the dissolution rate of pioglitazone. ANOVA 
indicated that the individual main effects of βCD, Poloxamer 407 and 
PVP K30 and their combined effects in enhancing the dissolution 
rate (K1) were highly significant (P<0.01) except in the case of ‘ac’. 
βCD alone gave an enhancement of 1.29 fold. Whereas in 
combination with Poloxamer 407 and PVP K30 gave a marginal 
enhancement (1.46 and 1.86 fold) in the dissolution rate of 
pioglitazone. Poloxamer 407 and PVP K30 have given highest 
enhancement (2.42 and 2.17 fold) in the dissolution rate of 
pioglitazone. 
Dissolution rate study of pioglitazone-βCD-poloxamer 407/PVP 
K30 tablets 
Pioglitazone tablets formulated employing drug-βCD-Poloxamer 
407/PVP K30 inclusion complexes and prepared by direct 
compression method disintegrated rapidly when compared to those 
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made by wet granulation method. Pioglitazone dissolution was rapid 
and higher from the tablets formulated employing drug-βCD-
Poloxamer 407/PVP K30 inclusion complexes when compared to the 
tablets containing pioglitazone alone in both wet granulation and 
direct compression methods. The individual as well as combined 
effects of the three factors involved i.e., βCD (factor A), Poloxamer 
407 (factor B) and PVP K30 (factor C) were highly significant 
(P<0.01) in enhancing the dissolution rate (K1) and dissolution 
efficiency (DE30) of pioglitazone in both wet granulation and direct 
compression methods. Among the three factors, Poloxamer 407 
(factor B) gave the highest enhancement in the dissolution rate (K1) 
and dissolution efficiency (DE30) of pioglitazone tablets in both wet 
granulation and direct compression methods. Out of all the βCD 
combinations, βCD-Poloxamer 407 combination has shown highest 
dissolution rate (K1) and selected for the pharmacokinetic studies. 
The alone βCD inclusion complex was also taken to evaluate the 
Poloxamer 407 effect in the pharmacokinetic study. All the studies 
were reported and given in brief in another paper [15]. 
Pharmacokinetic study 
The HPLC method validated was found suitable for the estimation of 
pioglitazone in plasma samples. The mobile phase consists of a mixture 
of acetonitrile-water (60: 40 v/v) adjusted to pH 6.0 with 0.1% v/v 
glacial acetic acid. The retention time for pioglitazone was 5.310 min and 
for internal standard (amikacin) it was 3.342 min. The linearity of the 
method was in the concentration range 1-5 µg/ml. The intra and 
interday coefficient of variation for drug and internal standard was less 
than 0.698 % showing the high precision of the method. The HPLC 
chromatograms of drug and internal standard were given in fig. 4. 
The pharmacokinetic evaluation was done on pioglitazone-βCD (1:2) 
and pioglitazone-βCD (1:2)-Poloxamer 407 (2%) inclusion complexes 
in comparison to pioglitazone pure drug with a view to evaluating the 
in vivo performance of pioglitazone-βCD complexes. Plasma 
concentrations of pioglitazone following the oral administration of 
pioglitazone and its βCD complexes are shown in fig. 5. The 
pharmacokinetic parameters estimated are summarized in table 3. 
The biological half-life (t1/2) estimated from the elimination phase of 
the plasma level curves was found to be 7.46, 7.28 and 7.18 h 
respectively following the oral administration of pioglitazone, and 
its CD complexes, pioglitazone-βCD (1:2) and pioglitazone-βCD 
(1:2)-Poloxamer 407 (2%) complexes. The t1/2 value of pioglitazone 
obtained in the present study is in good agreement with the 
literature reported [21] value of 6-10 h. The close agreement of the 
t1/2 values obtained with the three products indicated that the 
elimination characteristics of pioglitazone have not changed when it 
was administered as βCD complexes. 
Pioglitazone was found to be absorbed slowly when given orally and 
a peak plasma concentration (Cmax) of 11.40±0.7 µg/ml was 
observed at 4.0 h after administration. The absorption rate constant 
(Ka) was found to be 0.629 h-1. 
All the pharmacokinetic parameters (table 3) namely Cmax, Tmax, Ka 
and (AUC) 0∞indicated rapid and higher absorption and 
bioavailability of pioglitazone when administered as βCD complexes. 
Higher Cmax values and lower Tmax values were observed with the 
βCD complexes when compared to those of pioglitazone as such. The 
absorption rate constant (Ka) was found to be 2.16 h-1 and 2.94 h-1 
respectively with pioglitazone-βCD (1:2) complexes and 
pioglitazone-βCD (1:2)-Poloxamer 407 (2%) complexes. Whereas in 
the case of pioglitazone, Ka was only 0.629 h-1. A 3.43 and 4.67 fold 
increase in the absorption rate (Ka) was observed respectively with 
pioglitazone-βCD (1:2) and pioglitazone-βCD (1:2)-Poloxamer 407 
(2%) complexes when compared to pioglitazone pure drug. (AUC)0∞ 
(extent of absorption) was also much higher in the case of βCD 
complexes when compared to pioglitazone pure drug. (AUC)0∞was 
increased from 152.27 µg. h/ml for pioglitazone pure drug to 226.81 
and 254.01 µg. h/ml respectively for pioglitazone-βCD (1:2) and 
pioglitazone-βCD (1:2)-Poloxamer 407 (2%) complexes. A 1.49 and 
1.67 fold increase in (AUC)0∞was observed respectively with 
pioglitazone-βCD (1:2) and pioglitazone-βCD (1:2)-Poloxamer 407 
(2%) complexes when compared to pioglitazone pure drug. 
Thus, pioglitazone-βCD (1:2)-Poloxamer 407 solid inclusion 
complexes exhibited markedly higher rates and extent of absorption 
of pioglitazone when compared to pioglitazone alone and 
pioglitazone-βCD (1:2) complexes. Combination of βCD with 
Poloxamer 407 gave higher rates of absorption and bioavailability of 
pioglitazone than is possible with βCD alone. 
 
Table 1: Solubility of pioglitazone in various fluids as per 23 factorial study 
Fluids (code as per 23-factorial experiment) Solubility (mg/ml) (n=4) 
(x±SD) 
Increase in solubility 
(number of folds) 
Significance 
Distilled water (1) 0.122±0.08 - - 
Water containing 5 mmol βCD (a) 0.418±0.01 3.42 P<0.05 
Water containing 2% Poloxamer (b) 0.527±0.043 4.32 P<0.01 
Water containing 5 mmol βCD and 2% Poloxamer (ab) 1.691±0.052 13.85 P<0.01 
Water containing 2% PVP (c) 1.165±0.054 9.54 P<0.01 
Water containing 5 mmol βCD and 2% PVP (ac) 0.863±0.062 7.06 P<0.01 
Water containing 2% Poloxamer and 2% PVP (bc) 1.667±0.085 13.65 P>0.05 
Water containing 5 mmol βCD, 
2% Poloxamer and 2% PVP (abc) 
1.779±0.303 14.57 P<0.01 
βCD: β Cyclodextrin, Poloxamer: Poloxamer 407 and PVP: Polyvinylpyrrolidone K30, (n= 4, Data presented as mean±SD) 
 







Increase in K1  
(no. of folds) 
DE30 (%) Increase in DE30  
(no. of folds) 
F1 PIO 51.19 4.62 - 16.36 - 
Fa PIO-βCD (1:2) 59.92 5.98 1.29 19.46 1.19 
Fb PIO-P 407 (2%) 80.89 11.16 2.42 24.08 1.47 
Fab PIO-βCD (1:2)-P 407 (2%) 70.71 6.73 1.46 20.98 1.28 
Fc PIO-PVP (2%) 81.86 10.01 2.17 21.22 1.30 
Fac PIO-βCD (1:2)-PVP (2%) 78.30 8.59 1.86 23.03 1.41 
Fbc PIO-P 407 (2%)-PVP (2%) 89.82 10.28 2.23 25.36 1.55 
Fabc PIO-βCD (1:2)-P 407(2%)-
PVP (2%) 
66.22 7.86 1.70 21.89 1.34 
PIO: Pioglitazone; βCD: β Cyclodextrin; P 407: Poloxamer 407; PVP: Polyvinylpyrrolidone K30, (n=3, Data presented as mean) 
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Table 3: Summary of pharmacokinetic parameters estimated following the oral administration of pioglitazone and its βCD complexes 
Parameter Pioglitazone Pioglitazone-βCD (1:2) complex Pioglitazone-βCD (1:2)–poloxamer 407 (2%) complex 
Cmax (µg/ml) (±SD) 11.40±0.7 22.81±0.8 24.48±1.4 
Tmax (h) 4.0 2.0 1.0 
Kel (h-1) 0.093 0.095 0.097 
t ½ (h) 7.46 7.28 7.18 
(AUC)0[12]h (µg. h/ml) 92.14 155.03 172.67 
(AUC)0α (µg. h/ml) 152.27 226.81 254.01 
BA (%) 100 148.95 166.81 
Ka (h-1) 0.629 2.16 2.94 
Percent Absorbed 
0.5 h 24.4 71.2 86.9 
1.0 h 39.8 88.5 94.7 
2.0 h 60.6 100.0 100.0 
 βCD: β Cyclodextrin; n= 6, Data presented as mean±SD. 
 
 
Fig. 1: FTIR spectra of a) pioglitazone and b) pioglitazone-βCD-Poloxamer 407-PVP K30 complex 
 
 
Fig. 2: DSC thermogram of a) pioglitazone and b) pioglitazone-βCD-Poloxamer 407-PVP K30 Complexes 
 
 
Fig. 3: Dissolution profiles of pioglitazone-βCD-Poloxamer 407-PVP K30 solid inclusion complexes prepared as per 23 factorial study (n=3, 
Data presented as mean±SD) 1: Pure Drug; a: Pio-βCD; b: Pio-Poloxamer; ab: Pio-βCD-Poloxamer; c: Pio-PVP K30; ac: Pio-βCD-PVP K30; 
bc: Pio-Poloxamer-PVP K30; abc: Pio-βCD-Poloxamer-PVP K30 
Kovvasu et al. 




Fig. 4: HPLC chromatogram of pioglitazone (1 µg/0.5 ml of plasma) 
 
 
Fig. 5:  Plasma concentrations of pioglitazone following the oral administration of pioglitazone and its βCD complexes in rabbits (n=6, 
Data presented as mean ±SD) 
 
CONCLUSION 
Combination of βCD with Poloxamer 407 and PVP K30 resulted in a 
much higher enhancement (13.85-7.06 fold) in the solubility of 
pioglitazone than the βCD alone. Though PVP K30 has given highest 
enhancement (9.54 fold) in the solubility of pioglitazone, it gave only 
a marginal increase in the dissolution rate, K1 (1.96 fold) and DE30 
(1.34 fold). The t1/2 value of pioglitazone estimated (6.92 h-7.46 h) in 
the present study is in good agreement with the literature reported 
value of 6-10 h. The elimination characteristics of pioglitazone have 
not changed when it was administered as βCD complexes. 
Pioglitazone was absorbed slowly when given orally with an 
absorption rate constant (Ka) of 0.629 h-1and a peak plasma 
concentration (Cmax) of 11.40±0.7 µg/ml was observed at 4.0 h after 
administration. A 3.43 and 4.67 fold increase in the absorption rate 
(Ka) and a 1.49 and 1.67 fold increase in (AUC)0∞was observed 
respectively with pioglitazone-βCD (1:2) and pioglitazone-βCD (1:2)-
Poloxamer 407 (2%) complexes when compared to pioglitazone pure 
drug. Pioglitazone-βCD (1:2)-Poloxamer 407 (2%) solid inclusion 
complexes exhibited markedly higher rates and extent of absorption of 
pioglitazone when compared to pioglitazone alone and pioglitazone-
βCD (1:2) complexes. Combination of βCD with Poloxamer 407 gave 
higher rates of absorption and bioavailability of pioglitazone than is 
possible with βCD alone. Hence the combination of βCD with 
Poloxamer 407 is recommended to enhance the absorption and 
bioavailability of pioglitazone, a BCS class II drug. 
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